***Pharmaceutical Benefits Advisory Committee***

Email: PBAC@health.gov.au Address all mail to:

 PBAC Secretariat

 GPO Box 9848

 Canberra ACT 2601

**DELISTING OF PHARMACEUTICAL BENEFIT ITEMS**

**EFFECTIVE 01 AUGUST 2025**

Following is the advice of the Pharmaceutical Benefits Advisory Committee (PBAC) concerning the delisting of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act* *1953*, with effect from the above date.

|  |  |
| --- | --- |
| **Item** | **PBAC Advice** |
| Betaxolol | The sponsor requested the delisting of Betoptic (betaxolol) from the Pharmaceutical Benefits Scheme (PBS).The PBAC noted the moderate number of services in the last financial year. The PBAC advised the delisting of this product may result in an unmet clinical need and requested that the Department seek to retain the item on the PBS if possible. However, the sponsor decided to proceed with the delisting as the product is being discontinued due to manufacturing reasons. |
| Quinapril with hydrochlorothiazide | The sponsor requested the delisting of Accuretic 10/12.5mg tablet 10 mg quinapril (as hydrochloride) with 12.5 mg hydrochlorothiazide and Accuretic 20/12.5mg tablet 20 mg quinapril (as hydrochloride) with 12.5 mg hydrochlorothiazide (quinapril with hydrochlorothiazide) from the Pharmaceutical Benefits Scheme (PBS).The PBAC noted the low number of services in the last financial year and that there are multiple alternatives listed on the PBS. The PBAC advised the delisting of this product would not result in an unmet clinical need. |
| Tenecteplase | The sponsor requested the delisting of Metalyse (tenecteplase) from the Pharmaceutical Benefits Scheme (PBS).The PBAC noted the low number of services in the previous financial year and emphasised the need to retain this product as there are no suitable alternatives available on the PBS. The PBAC advised the delisting of this product may result in an unmet clinical need and requested that the Department seek to retain the item on the PBS if possible. However, the sponsor decided to proceed with the delisting as the product is being discontinued due to manufacturing reasons. |

Jodette Kotz

Director, PBS Supply and Policy

Pricing and PBS Policy Branch

Technology Assessment and Access Division

18 July 2025